متابعة القراءة
المقال الكامل على Bloomberg
US, Lilly, Novo to Announce Deal to Cut GLP-1 Prices (Trump's Remarks)
{# Share Buttons Partial Variables: share_title — text to pre-fill in share dialogs share_url — canonical URL to share (use request.build_absolute_uri in parent) #}تحليل معلومات السوق
مدعوم بالذكاء الاصطناعي
لماذا هذا مهم
Eli Lilly and Novo Nordisk have secured deals with the Trump administration to cut prices for their GLP-1 weight-loss drugs in exchange for tariff relief and wider Medicare access.
تأثير السوق
Market impact analysis based on bullish sentiment with 80% confidence.
المشاعر
Bullish
ثقة الذكاء الاصطناعي
80%
سياق المقال
ملاحظة: هذا مقتطف موجز للسياق. انقر أدناه لقراءة المقال الكامل على المصدر الأصلي.
Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. The deals with Lilly and Novo, announced Thursday at a White House event with President Donald Trump, will make some of the most popular drugs in the world available to certain people on Medicare, the government health plan for older Americans, according to senior administration officials. (Source: Bloomberg)
المقال الأصلي منشور بواسطة
Bloomberg
في نوفمبر 6, 2025.
التحليل والرؤى المقدمة من AnalystMarkets AI.
التحليل والرؤى المقدمة من AnalystMarkets AI.